Agios Pharmaceuticals (AGIO) Goldman Sachs 45th Annual Global Healthcare Conference summary

Clinical development highlights

• Lead product mitapivat (PYRUKYND) showed strong results in two pivotal Phase III thalassemia trials, meeting primary and key secondary endpoints, including transfusion reduction and fatigue improvement.

• ENERGIZE-T achieved nearly 10% transfusion independence and durable response up to 36 weeks, with plans to file with the FDA by year-end and a potential 2025 launch.

• Phase III sickle cell disease trial is on track for full enrollment by end of 2024, aiming for data in 2025 and a 2026 launch, following positive Phase II results.

• Both alpha and beta thalassemia patients responded well, supporting broad label inclusion and simplifying commercial messaging.

• Next-generation PK activator AG-946 in low-risk myelodysplastic syndrome showed 40% transfusion independence in Phase IIa; Phase IIb to start mid-year with higher doses.

Commercial and strategic outlook

• Commercial team is preparing for thalassemia launch in 2025, with education efforts targeting both clinicians and patients, especially in non-transfusion-dependent populations.

• Ex-US strategy prioritizes the Gulf region, with 70,000 thalassemia patients, seeking full-service distributor partnerships.

• PKD market remains slow but steady, serving as a real-world platform for future launches.

• AG-946 offers higher potency and no aromatase inhibition, with pricing and therapeutic optionality in new indications.

• Strong competitive position with two positive Phase III trials and a differentiated oral therapy in PK activation.

Financial position and pipeline expansion

• Monetization of vorasidenib royalty generated $905 million, with an additional $200 million milestone and 3% royalty on US sales above $1 billion, strengthening the balance sheet.

• Pipeline includes a PAH stabilizer (AG-181) in Phase I for PKU and an siRNA asset for polycythemia vera, targeting high unmet needs.

• Focus remains on advancing late-stage programs, successful launches, and disciplined business development for value enhancement.